Dipeptidyl peptidase‐4 inhibitors moderate the risk of genitourinary tract infections associated with sodium‐glucose co‐transporter‐2 inhibitors

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|20|3|740-744

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.20, Iss.3, 2018-03, pp. : 740-744

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 616-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 582-589

John Wiley & Sons Inc

Access to resources Recommend Favorite

How attractive is the combination of a sodium glucose co‐transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 613-615

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sodium–glucose cotransporter 2 inhibitors and renal function钠‐葡萄糖共转运体2抑制剂与肾功能

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 3, 2015-05 ,pp. : 295-298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 458-462

John Wiley & Sons Inc

Access to resources Recommend Favorite